Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

KB Home Shares Face Mounting Pressure as Short Interest Climbs

Robert Sasse by Robert Sasse
September 10, 2025
in Analysis, Real Estate & REITs, Trading & Momentum
0
KB Home Stock
0
SHARES
178
VIEWS
Share on FacebookShare on Twitter

KB Home’s stock is underperforming the broader homebuilder sector, declining 2.80% to $65.92. While industry peers are posting strong gains, the company contends with a significant rise in bearish bets and conflicting analyst assessments.

Fundamental Performance Shows Strain

Recent quarterly results reveal clear operational challenges. Revenue fell 10.5% to $1.53 billion, while earnings per share dropped sharply from $2.15 to $1.50. Current projections anticipate a 23.3% decline in profit for this year, though analysts forecast a potential recovery with an 8.55% increase next year. Despite these headwinds, valuation metrics appear attractive with a price-to-earnings ratio of 8.95.

Short Sellers Target Homebuilder

A notable development for KB Home is the substantial increase in short interest. Currently, 6.16 million shares have been sold short, representing 9.43% of the free float. This marks a 12.20% surge within just one month, indicating growing skepticism among investors. The Days to Cover ratio stands at 4.0, suggesting increased vulnerability to positive news catalysts that could trigger a short squeeze.

Should investors sell immediately? Or is it worth buying KB Home?

Divergence From Sector Strength

The company’s weakness contrasts sharply with sector performance. Over the past four weeks, the homebuilding industry has advanced 15.7%, significantly outpacing KB Home’s performance. This discrepancy suggests investors are focusing on company-specific concerns rather than broader industry optimism.

Mixed Analyst Sentiment Persists

Market experts remain divided on KB Home’s prospects:

  • Oppenheimer initiated coverage with a “Perform” rating, acknowledging opportunities in the build-to-order model while noting concerns about market positioning
  • Raymond James maintained its “Outperform” recommendation, highlighting what it views as an attractive risk/reward profile
  • Keefe, Bruyette & Woods reduced its price target to $58, citing margin compression and lowered delivery forecasts

The critical question remains whether KB Home can deliver on next year’s expected recovery or face additional pressure from short sellers if performance continues to disappoint.

Ad

KB Home Stock: Buy or Sell?! New KB Home Analysis from February 7 delivers the answer:

The latest KB Home figures speak for themselves: Urgent action needed for KB Home investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

KB Home: Buy or sell? Read more here...

Tags: KB Home
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Potbelly Stock
Analysis

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

February 7, 2026
Bank7 Stock
Analysis

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

February 7, 2026
Next Post
Robinhood Stock

Robinhood's Strategic Expansion: From Broker to Financial Powerhouse

American Eagle Outfitters Stock

Marketing Prowess Fuels American Eagle Outfitters' Stellar Quarter

Rocket Lab USA Stock

Rocket Lab Navigates Legal Challenges While Pushing Ambitious Space Agenda

Recommended

Torrid Holdings Stock

Torrid Holdings Faces Critical Earnings Test

5 months ago
Take-Two Stock

Take-Two Shares in Holding Pattern as Investors Await GTA VI Details

6 months ago
Union Pacific Stock

Union Pacific’s Future Hangs in Balance as Historic Railroad Merger Faces Critical Vote

4 months ago
Biotechnology Markets and money

BioTechnes Quarterly Earnings and Stock Performance Analysis

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Claros Mortgage Trust Secures Financial Flexibility Through Strategic Debt Overhaul

Trending

Vigil Neuroscience Stock
Healthcare

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

by SiterGedge
February 7, 2026
0

The integration of Vigil Neuroscience into French pharmaceutical giant Sanofi has been finalized. This strategic move, which...

Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Potbelly Stock

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success
  • Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com